Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PZ HTL SA

Inherited Orphan Blood Diseases Patients Face Stagnant Treatment Future

By BiotechDaily International staff writers
Posted on 28 Jan 2013
Uninspiring treatment options combined with feeble product pipelines typically will lead to modest growth for several inherited orphan blood disease markets, according to recent market research.

According to the business intelligence provider GBI Research’s (New York, NY, USA) new report, the global therapeutic markets for sickle cell thalassemia, sickle cell anemia, and hereditary angioedema (HAE) are all expected to show unimpressive growth. The greatest value increase is expected from the sickle cell anemia market, which is forecast to rise at a compound annual growth rate (CAGR) of 9%, from USD 36 million in 2012 to USD 70 million in 2019.

In the meantime, the global HAE therapeutics market is predicted to increase at a miserly CAGR of 3% during the same period, from USD 1.5–1.9 billion. Kimberley Carter, associate analyst at GBI Research, stated, “Even though orphan blood disorders are rare, the three diseases featured in this report are hereditary and have a large impact on the lives of the families and ethnic groups afflicted by these diseases. Many of these diseases cause debilitating health issues and limit lifespan. Because of this, there is a great need for curative and disease modifying therapies. While this may require significant R&D investment, any drugs that are successful in treating these diseases can be expected to be priced at the highest premium range.”

All three disorders examined in the new report have weak product pipelines, with most upcoming treatments either too similar to currently available options, or insufficiently promising to make any real impact.

Presently, only the HAE market can be considered strong, due mostly to the dominance of Cinryze—the only branded therapy taken according to a regular dosing regimen. Cinryze will continue to dominate the HAE market as long as it remains unique, and an exceptionally weak pipeline will most likely ensure this remains the case.

GBI Research is a provider of business intelligence reports, providing data and forecasts based on the insights of key industry leaders to ensure up-to-date with the latest emerging trends in markets.

Related Links:

GBI Research




BIOSIGMA S.R.L.
SLAS - Society for Laboratory Automation and Screening
RANDOX LABORATORIES
comments powered by Disqus

Channels

Drug Discovery

view channel

Omega 3 Found to Improve Behavior in Children with ADHD

Supplements of the fatty acids omega 3 and 6 can help children and adolescents who have a specific kind of have attention deficit hyperactivity disorder (ADHD). Moreover, these findings indicate that a customized cognitive training program can improve problem behavior in children with ADHD. Statistics show that 3%–6%... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Lab Technologies

view channel
Image: On target: When researchers introduced nanobodies they made to cells engineered to express a tagged version of a protein in skeletal fibers known as tubulin (red), the nanobodies latched on. The cells above have recently divided (Photo courtesy of Rockefeller University).

Turning Antibodies into Precisely Tuned Nanobodies

New technology has the potential to create nanobodies making them much more accessible than antibodies for all sorts of research. Antibodies control the process of recognizing and zooming in on molecular... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.